Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow, +23

New England Journal of Medicine

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab

Nadeem Riaz, Jonathan J. Havel, Vladimir Makarov, +22

Cell

Microenvironment EvolutionTumor ImmunologyCancer ImmunosurveillanceImmunologyImmune Checkpoint Inhibitor +4

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

Jeffrey S. Weber, Mario Mandalà, Michele Del Vecchio, +31

New England Journal of Medicine

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

Paul Nghiem, Shailender Bhatia, Evan J. Lipson, +28

New England Journal of Medicine

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

Howard L. Kaufman, Jeffery S. Russell, Omid Hamid, +15

The Lancet Oncology

MedicineMetronomic TherapyPathologyCancer TreatmentOncology +1

Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

John A. Thompson, Bryan J. Schneider, Julie R. Brahmer, +28

Journal of the National Comprehensive Cancer Network

Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics

Kelly G. Paulson, Song Youn Park, Natalie Vandeven, +8

Journal of the American Academy of Dermatology

Current Us IncidenceCancer EpidemiologyMedicineEpidemiology Of CancerPathology +6

NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020

John A. Thompson, Bryan J. Schneider, Julie R. Brahmer, +29

Journal of the National Comprehensive Cancer Network

Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy

Paul Nghiem, Shailender Bhatia, Evan J. Lipson, +28

Journal of Clinical Oncology

Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma

Catherine S. Grasso, Jennifer Tsoi, Mykola Onyshchenko, +33

Cancer Cell

Tumor ImmunologyCancer ImmunosurveillanceMelanomaImmunologyTumor Immunity +5